Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
365 studies found for:    "Mycosis fungoides"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
Conditions: Recurrent Mycosis Fungoides;   Refractory Mycosis Fungoides;   Stage I Mycosis Fungoides;   Stage II Mycosis Fungoides;   Stage III Mycosis Fungoides
Interventions: Other: Quality-of-Life Assessment;   Other: Objective Grading of Skin Findings
2 Active, not recruiting Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome;   Stage IB Mycosis Fungoides and Sezary Syndrome;   Stage IIA Mycosis Fungoides and Sezary Syndrome;   Stage IIB Mycosis Fungoides and Sezary Syndrome;   Stage IIIA Mycosis Fungoides and Sezary Syndrome;   Stage IIIB Mycosis Fungoides and Sezary Syndrome;   Stage IVA Mycosis Fungoides and Sezary Syndrome;   Stage IVB Mycosis Fungoides and Sezary Syndrome
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
3 Terminated Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions: Biological: aldesleukin;   Biological: recombinant interleukin-12;   Other: laboratory biomarker analysis
4 Completed
Has Results
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Condition: Mycosis Fungoides
Intervention: Drug: mechlorethamine-MCH (nitrogen mustard)
5 Recruiting Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Condition: Mycosis Fungoides
Intervention: Drug: Valchlor
6 Terminated Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: HuMax-CD4 (zanolimumab)
7 Unknown  Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: alemtuzumab
8 Recruiting Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Campath-1H
9 Completed Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
Conditions: Cutaneous T Cell Lymphoma;   Mycosis Fungoides
Intervention: Drug: Methoxsalen+ECP
10 Active, not recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma;   Lymphoma, Primary Cutaneous Anaplastic Large Cell;   Lymphomatoid Papulosis;   Mycosis Fungoides;   Skin Lymphoma;   Cutaneous Lymphomas;   Lymphoma;   Hematologic Disorder
Intervention: Drug: SGN-35
11 Recruiting PUVA Maintenance Therapy in Mycosis Fungoides
Condition: Patch/Plaque Stage Mycosis Fungoides
Intervention: Drug: 8-methoxypsoralen
12 Terminated Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides
Condition: Mycosis Fungoides
Intervention: Device: Low-dose total skin electron beam therapy (4 Gy)
13 Terminated Phase II Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides
Conditions: Mycosis Fungoides;   Lymphomas: Non-Hodgkin;   Lymphomas: Non-Hodgkin Peripheral T-Cell;   Lymphomas: Non-Hodgkin Cutaneous Lymphoma
Intervention: Device: Total Skin Electron Beam Therapy (TSEBT)
14 Not yet recruiting TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome
Conditions: Mycosis Fungoides;   Sézary Syndrome
Interventions: Radiation: TSEB Therapy;   Drug: Brentuximab vedotin
15 Not yet recruiting ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Conditions: Mycosis Fungoides;   Non-Hodgkin's Lymphoma
Intervention:
16 Not yet recruiting Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
Conditions: Mycosis Fungoides;   Cutaneous T-cell Lymphoma
Interventions: Radiation: Total skin electron beam therapy (TSEBT);   Drug: mechlorethamine gel 0.016%
17 Not yet recruiting Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Conditions: Solid Tumors;   Mycosis Fungoides;   Melanoma;   Merkel-cell Carcinoma;   Squamous Cell Carcinoma;   Breast Carcinoma;   Human Papillomavirus-Related Malignant Neoplasm;   Soft Tissue Sarcoma
Intervention: Drug: TTI-621
18 Withdrawn Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
Condition: Mycosis Fungoides
Intervention: Drug: CPG 7909
19 Completed An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
Condition: Mycosis Fungoides
Intervention: Drug: 0.04% Mechlorethamine gel
20 Terminated PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides
Condition: Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Interventions: Drug: PUVA (8MOP + UVA) + IFN;   Drug: PUVA (8-MOP + UVA)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years